Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-NYM032 in progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
CTR20263307Phase 3Active
- Sponsor
- Norroy Bioscience
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NY108 in prostate cancer (PCa), sponsored by Norroy Bioscience. Started Aug 2026; status: active.
02
Drugs
NY108
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20263307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263307.